Delivering transformative treatments to cancer patients

<p><span data-contrast="auto">In the</span><a href= "https://www.ddw-online.com/t/in-conversation-series/"><em><span data-contrast="auto"> In Conversation With</span></em> </a><span data-contrast= "auto">series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. </span> <span data-ccp-props= "{"201341983":0,"335559739":160,"335559740":259}"> </span></p> <p><span data-ccp-props= "{"201341983":0,"335559739":160,"335559740":259}"> In this episode, Megan Thomas is in </span>conversation with Shelley Ackerman, a biological engineer turned immunologist with a passion for drug discovery and development. She has been honoured as one of MIT Technology Review's Innovators Under 35 (2021), STAT Wunderkind (2021), and San Francisco Business Times' Women Who Lead in Life Sciences, The Next Generation of Life Sciences Researchers (2022), and today she speaks about the work being carried out at Bolt BioTherapeutics, where she is the Director & Program Team Lead.</p>